High prevalence of macrolide resistance in mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China

Clinical Infectious Diseases

Volumn 51, Issue 2, 2010, Pages 189-194

  Cao, Bin ^a   Zhao, Chun Jiang ^c   Yin, Yu Dong ^a   Zhao, Fei ^d   Song, Shu Fan ^a   Bai, Lu ^a   Zhang, Jian Zhong ^d   Liu, Ying Mei ^a   Zhang, Yu Yu ^a   Wang, Hui ^c   Wang, Chen ^b  

^a Clinical Microbiology   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MINOCYCLINE; MOXIFLOXACIN; RIBOSOME RNA; SPIRAMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT; BACTERIAL DNA; RNA 23S;

ADOLESCENT; ADULT; AMBULATORY CARE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHINA; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NUCLEOTIDE SEQUENCE; POINT MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THORAX RADIOGRAPHY; THROAT CULTURE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; ANTIBIOTIC RESISTANCE; CHEMISTRY; CHILD; DNA SEQUENCE; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MOLECULAR GENETICS; RNA GENE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHINA; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FEMALE; GENES, RRNA; HUMANS; MACROLIDES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA; POINT MUTATION; RNA, RIBOSOMAL, 23S; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954729202     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653535     Document Type: Article

References (21)

1. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004; 17:697-728.
2. Hammerschlag MR. Mycoplasma pneumoniae infections. Curr Opin Infect Dis 2001; 14:181-186.
3. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother 2010; 16:78-86.
4. McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429-437.
5. Liu Y, Chen M, Zhao T, et al. Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population. BMC Infect Dis 2009; 9:31-40.
6. Matsuoka M, Narita M, Okazaki N, et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clini cal isolates obtained in Japan. Antimicrob Agents Chemother 2004; 48: 4624-4630.
7. Morozumi M, Hasegawa K, Kobayashi R, et al. Emergence of macrolide- resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob Agents Chemother 2005; 49:2302-2306.
8. Okazaki N, Narita M, Yamada S, et al. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol 2001; 45:617-620.
9. Dumke R, von Baum H, Lück PC, Jacobs E. Occurrence of macrolideresistant Mycoplasma pneumoniae strains in Germany. Clin Microbiol Infect 2009; 16:613-616.
10. Peuchant O, Menard A, Renaudin H, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009; 64:52-58.
11. Morozumi M, Iwata S, Hasegawa K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with communityacquired pneumonia. Antimicrob Agents Chemother 2008; 52:348-350.
12. Xin D, Mi Z, Han X, et al. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother 2009; 53:2158-2159.
13. Liu Y, Ye X, Zhang H, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother 2009; 53:2160-2162.
14. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify lowrisk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250.
15. Waites KB, Bebear CM, Robertson JA, Talkington DF, Kenny GE. Cumitech 34, laboratory diagnosis of mycoplasmal infections. F. S. Nolte, coordinating ed. Washington, DC: American Society for Microbiology, 2001.
16. Himmelreich R, Hilbert H, Plagens H, Pirkl E, Li B, Herrmann R. Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae. Nucleic Acids Res 1996; 24:4420-49. (Pubitemid 26388629)
17. Cousin-Allery A, Charron A, de Barbeyrac B, et al. Molecular typing of Mycoplasma pneumoniae strains by PCR-based methods and pulsedfield gel electrophoresis: application to French and Danish isolates. Epidemiol Infect 2000; 124:103-111.
18. Herschleb J, Ananiev G, Schwartz DC. Pulsed-field gel electrophoresis. Nat Protoc 2007; 2:677-84.
19. Isozumi R, Yoshimine H, Morozumi M, Ubukata K, Ariyoshi K. Adult community-acquired pneumonia caused by macrolide resistant Mycoplasma pneumoniae. Respirology 2009; 14:1206-1208.
20. Waites KB, Balish MF, Atkinson TP. New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol 2008; 3:635-48.
21. Suzuki S, Yamazaki T, Narita M, et al. Clinical evaluation of macrolideresistant Mycoplasma pneumoniae. Antimicrob Agents Chemother 2006; 50:709-12.